TGF-β and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells

Journal of Immunology

Volumn 174, Issue 4, 2005, Pages 2061-2070

  Lyakh, Lyudmila A ^a   Sanford, Michael ^b   Chekol, Sebel ^a   Young, Howard A ^b   Roberts, Anita B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM IONOPHORE; COLECALCIFEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CREL; TRANSCRIPTION FACTOR RELB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 13544264776     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.4.2061     Document Type: Article

References (79)

1. Sundquist, M., C. Johansson, and M. J. Wick. 2003. Dendritic cells as inducers of antimicrobial immunity in vivo. APMIS 111:715.
2. Gad, M., M. H. Claesson, and A. E. Pedersen. 2003. Dendritic cells in peripheral tolerance and immunity. APMIS 111:766.
3. Steinman, R. M. 2003. Some interfaces of dendritic cell biology. APMIS 111:675.
4. Randolph, G. J., K. Inaba, D. F. Robbiani, R. M. Steinman, and W. A. Muller. 1999. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11:753.
5. Randolph, G. J., S. Beaulieu, S. Lebecque, R. M. Steinman, and W. A. Muller. 1998. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282:480.
6. + monocytes through distinct pathways that activate NK-κB. J. Immunol. 165:3647.
7. + monocytes cultured under serum-free conditions. Blood 99:600.
8. + dendritic cells is modulated under serum-free conditions by exogenously added IFN-γ and endogenously produced IL-10. Eur. J. Immunol. 31:3773.
9. Borkowski, T. A., J. J. Letterio, A. G. Farr, and M. C. Udey. 1996. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184:2417.
10. Borkowski, T. A., J. J. Letterio, C. L. Mackall, A. Saitoh, X. J. Wang, D. R. Roop, R. E. Gress, and M. C. Udey. 1997. A role for TGFβ1 in Langerhans cell biology: further characterization of the epidermal Langerhans cell defect in TGFβ1 null mice. J. Clin. Invest. 100:575.
11. Borkowski, T. A., J. J. Letterio, C. L. Mackall, A. Saitoh, A. G. Farr, X. J. Wang, D. R. Roop, R. E. Gress, and M. C. Udey. 1997. Langerhans cells in the TGF β1 null mouse. Adv. Exp. Med. Biol. 417:307.
12. Hacker, C., R. D. Kirsch, X. S. Ju, T. Hieronymus, T. C. Gust, C. Kuhl, T. Jorgas, S. M. Kurz, S. Rose-John, Y. Yokota, and M. Zenke. 2003. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4:380.
13. Gorelik, L., and R. A. Flavell. 2002. Transforming growth factor-β in T-cell biology. Nat. Rev. Immunol. 2:46.
14. Strobl, H., and W. Knapp. 1999. TGF-β1 regulation of dendritic cells. Microbes Infect. 1:1283.
15. Mathieu, C., and L. Adorini. 2002. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 8:174.
16. Griffin, M. D., W. Lutz, V. A. Phan, L. A. Bachman, D. J. McKean, and R. Kumar. 2001. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:6800.
17. Hackstein, H., and A. W. Thomson. 2004. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4:24.
18. Penna, G., and L. Adorini. 2000. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164:2405.
19. Piemonti, L., P. Monti, M. Sironi, P. Fraticelli, B. E. Leone, E. Dal Cin, P. Allavena, and V. DiCarlo, V. 2000. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 164:4443.
20. Hewison, M., L. Freeman, S. V. Hughes, K. N. Evans, R. Bland, A. G. Eliopoulos, M. D. Kilby, P. A. Moss, and R. Chakraverty. 2003. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 170:5382.
21. Cao, Z., K. C. Flanders, D. Bertolette, L. A. Lyakh, J. U. Wurthner, W. T. Parks, J. J. Letterio, F. W. Ruscetti, and A. B. Roberts. 2003. Levels of phosphoSmad2/3 are sensors of the interplay between effects of TGF-β and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 101:498.
22. Danielpour, D. 1996. Induction of transforming growth factor-β autocrine activity by all-trans-retinoic acid and 1α,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J. Cell. Physiol. 166:231.
23. Nagel, D., and R. Kumar. 2002. 1α,25-Dihydroxyvitamin D3 increases TGF β1 binding to human osteoblasts. Biochem. Biophys. Res. Commun. 290:1558.
24. Defacque, H., D. Piquemal, A. Basset, J. Marti, and T. Commes. 1999. Transforming growth factor-β1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J. Cell. Physiol. 178:109.
25. Subramaniam, N., G. M. Leong, T. A. Cock, J. L. Flanagan, C. Fong, J. A. Eisman, and A. P. Kouzmenko. 2001. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-β signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J. Biol. Chem. 276:15741.
26. Yanagi, Y., M. Suzawa, M. Kawabata, K. Miyazono, J. Yanagisawa, and S. Kato. 1999. Positive and negative modulation of vitamin D receptor function by transforming growth factor-β signaling through Smad proteins. J. Biol. Chem. 274:12971.
27. Czerniecki, B. J., C. Carter, L. Rivoltini, G. K. Koski, H. I. Kim, D. E. Weng, J. G. Roros, Y. M. Hijazi, S. Xu, S. A. Rosenberg, and P. A. Cohen. 1997. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol. 159:3823.
28. Koski, G. K., G. N. Schwartz, D. E. Weng, R. E. Gress, F. H. Engels, M. Tsokos, B. J. Czerniecki, and P. A. Cohen. 1999. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 94:1359.
29. Rice, N. R., M. L. MacKichan, and A. Israel. 1992. The precursor of NF-κB p50 has IκB-like functions. Cell 71:243.
30. Whiteside, S. T., J. C. Epinat, N. R. Rice, and A. Israel. 1997. IκBε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 16:1413.
31. Young, H. A., J. J. Subleski, and S. M. Krebs. 2003. Multiprobe ribonuclease protection assay for simultaneous measurement of mRNA expression of 8-12 genes. In Current Protocols in Immunology. John Wiley and Sons, Hoboken, pp. 10.29.1-10.29.15.
32. Wrana, J. L., L. Attisano, R. Wieser, F. Ventura, and J. Massague. 1994. Mechanism of activation of the TGF-β receptor. Nature 370:341.
33. Winzler, C., P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V. S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J. Exp. Med. 185:317.
34. + dendritic cells. Proc. Natl. Acad. Sci. USA 93:2588.
35. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
36. + dendritic cells that induce Th2 cell development. Blood 98:2489.
37. D'Ambrosio, D., M. Cippitelli, M. G. Cocciolo, D. Mazzeo, P. Di Lucia, R. Lang, F. Sinigaglia, and P. Panina-Bordignon. 1998. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-κB down-regulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101:252.
38. Lore, K., A. Sonnerborg, A. L. Spetz, U. Andersson, and J. Andersson. 1998. Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. J. Immunol. Methods 214:97.
39. Re, F., and J. L. Strominger. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692.
40. Sallusto, F., B. Palermo, D. Lenig, M. Miettinen, S. Matikainen, I. Julkunen, R. Forster, R. Burgstahler, M. Lipp, and A. Lanzavecchia. 1999. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29:1617.
41. Moore, K. W., M. R. de Waal, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683.
42. McCartney-Francis, N., W. Jin, and S. M. Wahl. 2004. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-β1 signaling pathway. J. Immunol. 172:3814.
43. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499.
44. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618.
45. Ouaaz, F., J. Arron, Y. Zheng, Y. Choi, and A. A. Beg. 2002. Dendritic cell development and survival require distinct NF-κB subunits. Immunity 16:257.
46. Burkly, L., C. Hession, L. Ogata, C. Reilly, L. A. Marconi, D. Olson, R. Tizard, R. Cate, and D. Lo. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373:531.
47. Poljak, L., L. Carlson, K. Cunningham, M. H. Kosco-Vilbois, and U. Siebenlist. 1999. Distinct activities of p52/NF-κB required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J. Immunol. 163:6581.
48. Weih, F., D. Carrasco, S. K. Durham, D. S. Barton, C. A. Rizzo, R. P. Ryseck, S. A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 80:331.
49. Sanjabi, S., A. Hoffmann, H. C. Liou, D. Baltimore, and S. T. Smale. 2000. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc. Natl. Acad. Sci. USA 97:12705.
50. Stancovski, I., and D. Baltimore. 1997. NF-κB activation: the IκB kinase revealed? Cell 91:299.
51. Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, and B. Pulendran. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984.
52. Ardeshna, K. M., A. R. Pizzey, S. Devereux, and A. Khwaja. 2000. The P13 kinase, p38 SAP kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039.
53. Arrighi, J. F., M. Rebsamen, F. Roussel, V. Kindler, and C. Hauser. 2001. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers. J. Immunol. 166:3837.
54. Fukao, T., S. Matsuda, and S. Koyasu. 2000. Synergistic effects of 1L-4 and IL-18 on IL-12-dependent IFN-γ production by dendritic cells. J. Immunol. 164:64.
55. Roberts, A. B., and R. Derynck. 2001. Meeting report: signaling schemes for TGF-β. Sci. STKE 2001:E43.
56. Shi, Y., and J. Massague. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113:685.
57. + hemopoietic progenitors. J. Immunol. 157:1499.
58. Strobl, H., C. Bello-Fernandez, E. Riedl, W. F. Pickl, O. Majdic, S. D. Lyman, and W. Knapp. 1997. flt3 ligand in cooperation with transforming growth factor-β1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425.
59. Lu, L., W. Li, F. Fu, F. G. Chambers, S. Qian, J. J. Fung, and A. W. Thomson. 1997. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 64:1808.
60. Yamaguchi, Y., H. Tsumura, M. Miwa, and K. Inaba. 1997. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:144.
61. Geissmann, F., P. Revy, A. Regnault, Y. Lepelletier, M. Dy, N. Brousse, S. Amigorena, O. Hermine, and A. Durandy. 1999. TGF-β1 prevents the non-cognate maturation of human dendritic Langerhans cells. J. Immunol. 162:4567.
62. + T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol. 172:1991.
63. Alard, P., S. L. Clark, and M. M. Kosiewicz. 2004. Mechanisms of tolerance induced by TGFβ-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGFβ. Eur. J. Immunol. 34:1021.
64. Kao, J. Y., Y. Gong, C. M. Chen, Q. D. Zheng, and J. J. Chen. 2003. Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170:3806.
65. Kobie, J. J., R. S. Wu, R. A. Kurt, S. Lou, M. K. Adelman, L. J. Whitesell, L. V. Ramanathapuram, C. L. Arteaga, and E. T. Akporiaye. 2003. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63:1860.
66. Fritsche, J., K. Mondal, A. Ehrnsperger, R. Andreesen, and M. Kreutz. 2003. Regulation of 25-hydroxyvitamin D3-1α-hydroxylase and production of 1α,25-dihydroxyvitamin D3 by human dendritic cells. Blood 102:3314.
67. Ota, M., R. Amakawa, K. Uehira, T. Ito, Y. Yagi, A. Oshiro, Y. Date, H. Oyaizu, T. Shigeki, Y. Ozaki, et al. 2004. Involvement of dendritic cells in sarcoidosis. Thorax 59:408.
68. Defacque, H., T. Commes, V. Contet, C. Sevilla, and J. Marti. 1995. Differentiation of U937 myelomonocytic cell line by all-trans retinoic acid and 1,25-dihydroxyvitamin D3: synergistic effects on tissue transglutaminase. Leukemia 9:1762.
69. Dong, X., T. Craig, N. Xing, L. A. Bachman, C. V. Paya, F. Weih, D. J. McKean, R. Kumar, and M. D. Griffin. 2003. Direct transcriptional regulation of RelB by 1α,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 278:49378.
70. Martin, E., B. O'Sullivan, P. Low, and R. Thomas. 2003. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18:155.
71. Hutchings, A., W. J. Hubbard, F. T. Thomas, and J. M. Thomas. 2002. STEALTH in transplantation tolerance. Immunol. Res. 26:143.
72. Hutchings, A., J. Wu, C. Asiedu, W. Hubbard, D. Eckhoff, J. Contreras, F. T. Thomas, D. Neville, and J. M. Thomas. 2003. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transplant Immunol. 11:335.
73. Adams, J. S., and V. Kantorovich. 1999. Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. J. Clin. Endocrinol. Metab. 84:799.
74. Akhurst, R. J., and R. Derynck. 2001. TGF-β signaling in cancer: a double-edged sword. Trends Cell Biol. 11:S44.
75. Brown, R. D., B. Pope, A. Murray, W. Esdale, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua. 2001. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 98:2992.
76. Pasche, B. 2001. Role of transforming growth factor β in cancer. J. Cell. Physiol. 186:153.
77. Engleman, E. G., J. Brody, and L. Soares. 2004. Using signaling pathways to overcome immune tolerance to tumors. Sci. STKE 2004:e28.
78. Won, J., H. Kim, E. J. Park, Y. Hong, S. J. Kim, and Y. Yun. 1999. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res. 59:1273.
79. Gorelik, L., and R. A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:1118.